The intravulvosubmucosal (IVSM) route has been used to reduce the dose of prostaglandin F 2a (PGF 2a ), a luteolytic agent used in estrus synchronization programs. To validate the effectiveness of PGF 2a administered via IVSM, the estrus rate was monitored in 1937 beef cows for 5 days (25.6% of estrus). The cows that did not show signs of estrus by day 5 received 5 mg of dinoprost IVSM (1/5 of the standard dose; n ¼1440). By day 10, 68.2% of the cows were in estrus. In a second trial, using the same synchronization protocol, the proportion of heifers in estrus after receiving 5 mg dinoprost at day 5 via IVSM (47.4%; n ¼ 97) or via an intramuscular injection (IM; 54.7%; n ¼95) did not differ (P 40.05). The occurrence of luteolysis (serum progesterone concentrations below 1 ng/mL) was dependent on the period of the estrous cycle in which the cows were treated with 5 mg of dinoprost via IM or IVSM. Luteolysis was observed in 5 out of 10 cows treated at day 10 but was not observed in any cows treated at day 5 of the estrous cycle. Luteolysis occurred in all animals treated with 25 mg dinoprost independent of the estrous cycle period (day 5 or 10). After IVSM injection, the PGF 2a concentration did not differ in the uterine and jugular veins. This was further confirmed by measuring the concentration of 13,14-dihydro-15-keto-PGF 2a (PGFM) after the injection of 5 mg of dinoprost via the IM or IVSM route. Dinoprost IM and IVSM injections resulted in a similar PGFM serum pattern over time, indicating the same rate of absorption into the systemic circulation. Taking the results together, we concluded that PGF 2a IVSM injections reached the systemic circulation before reaching the ovary, and the effectiveness of low doses of PGF 2a was dependent on the period of the estrous cycle and not on the route of administration.
Introduction
The luteolytic agent prostaglandin F 2a (PGF 2a ) has been used extensively to manipulate the estrous cycle in cattle. Different routes of administration have been tested in an attempt to reduce the dose administered (Alvarez et al., 1991; Colazo et al., 2002a Colazo et al., , 2002b , which has resulted in estrus synchronization after intravulvosubmucosal (IVSM) injection (Alvarez et al., 1991; Chohan, 1998; Horta et al., 1986; Suñ e et al., 1985) , despite disagreement among different studies (Colazo et al., 2002b) . In a commercial context, our group synchronized more than 64,000 cows. We observed 79.8% of treated females in estrus after the IVSM administration of 5 mg of dinoprost (1/5 of the standard dose) using the 10-day, 1-injection management system reported by Donaldson et al. (1982) .
Brazil has the largest commercial herd in the world, with approximately 205 million heads. Productivity in heads per hectare has increased by 25% over the last 10 years (ABIEC, 2012) . Hormonal protocols are widely used in the management of bovine reproduction, and prostaglandin analogs are among the hormones used most commonly to control the estrous cycle (for review see Lamb et al., 2010) . Prostaglandin F 2a has been indicated for both reproductive biotechniques and the treatment of reproductive disorders (Alvarez et al., 1991; Colazo et al., 2002a; Inskeep, 1973; Salasel and Mokhtari, 2011) . Therefore, it is essential to understand the mechanisms involved in prostaglandin transport, metabolism and luteolysis to further develop methods that are more biologically efficient and profitable.
Some evidence indicates that an IVSM injection of PGF 2a reaches the ovaries independently of the systemic circulation (Alvarez et al., 1991; Chohan, 1998; Gioso et al., 2005; Horta et al., 1986; Suñ e et al., 1985) . The establishment of the reproductive tract angioarchitecture using contrasted radiography demonstrated many anastomoses between vulvar and utero-ovarian vessels (Ginther and Del Campo, 1974; Gioso et al., 2005) . These anatomic structures associated with the vascular countercurrent exchange mechanism between the ovarian artery and the utero-ovarian vein could allow PGF 2a injected via the IVSM to avoid the systemic metabolism before reaching the ovary. However, to our knowledge, there have been no studies about the local mechanisms of PGF 2a administered via the IVSM route.
Studies of different routes and doses of PGF 2a administration have evaluated the estrus response and serum progesterone concentrations without considering the responsiveness of the corpus luteum (CL) after treatment (Alvarez et al., 1991; Chohan, 1998; Colazo et al., 2002a) . Thus, the aims of the present study were the following: (1) to evaluate the effect of dose and administration route on estrous behavior, (2) to assess the onset of luteolysis in periods of low and high PGF 2a responsiveness, and (3) to determine the profile of PGF 2a and prostaglandin metabolite concentrations (13, ; PGFM) in the uterine and jugular veins after intramuscular (IM) or IVSM administration of a reduced dose of PGF 2a .
Materials and methods

Location, animals and feed
All protocols and procedures were approved by the Institutional Committee for Ethics in Animal Experiments at the Federal University of Santa Maria, RS, Brazil (23081.008212/2010-68) . The experiments were conducted during the spring and summer in southern Brazil, and all animals included in each experiment belonged to the same farm. The local weather is humid subtropical, type CfA, in accordance with Köppen's classification. This study included crossbred beef heifers and non-lactating cows (Bos taurus taurus) with body condition scores of 3 and 4 (1¼extremely thin, 5¼very fat) (Houghton et al., 1990) . All animals were managed under an extensive grazing system based on natural pastures and had free access to a mineral supplement and water. The animals used in the experiments involving estrous observation were managed in groups with 300 or fewer animals. Estrus detection was performed by visual observation for 60 min twice a day.
2.2. Experiment 1. Effect of a reduced-dose PGF 2a IVSM injection on estrous behavior Cycling, non-lactating beef cows (Bos taurus taurus) were used to validate the efficiency of 5 mg (1/5 of the standard dose) of dinoprost tromethamine (dinoprost; Lutalyse, Pfizer Animal Health, São Paulo, Brazil) via the IVSM in an estrus synchronization system. Beef cows (n¼1937) were synchronized with the 10-day, 1-injection management system (Donaldson et al., 1982) . Briefly, estrus detection was performed twice a day, at 12-h intervals for 5 d, which was considered as the control period. In the morning of day 5, only the cows that were not considered to be in estrus received a dose of 5 mg of dinoprost (IVSM; using a 21-gage, 2.5-cm needle). Estrous behavior was observed for an additional 5 d, as described above.
Experiment 2. Intramuscular vs. intravulvosubmucosal injection of PGF 2a
Non-pregnant cyclic beef heifers (n ¼251; 24-30 months old) were observed for estrous behavior twice a day for 5 d. The animals considered not to be in estrus during the first 5 days received 5 mg of dinoprost and were randomly placed in either the IM group (n ¼95; injection in the gluteal muscles using a 21-gage, 4-cm needle) or the IVSM (n ¼97) group. After treatment, estrous behavior was observed and recorded for 5 d.
2.4. Experiment 3. PGF 2a injection (IM or IVSM) at periods of low and high corpus luteum sensitivity Non-pregnant crossbred beef cows (n¼50) were synchronized with progestagen intravaginal devices containing 250 mg of medroxyprogesterone acetate and 2 mg estradiol benzoate at day zero. The devices were maintained for 7 days, and 0.250 mg of cloprostenol sodium (Ciosin; Intervet/Schering-Plough Animal Health, Cotia, Brazil) was administered at the time of device removal. Estrus detection was initiated at approximately 12 h after intravaginal device removal and was performed twice a day for 5 d. Thirty-eight cows were observed in estrus, and twenty-six were used in the experiment. The animals were randomly allocated to receive different doses of dinoprost on day 5 after estrus (low PGF 2a responsiveness): 25 mg IM, 5 mg IM, or 5 mg IVSM (n¼3/treatment); or day 10 after estrus (high PGF 2a responsiveness): 25 mg IM (n¼3), 5 mg IM (n¼5), or 5 mg IVSM (n¼ 5). Two cows at day 5 and two cows at day 10 of the estrous cycle were used as controls and were not treated. The blood samples for progesterone analysis were collected by caudal venipuncture once a day for 5 d, starting at the time of the dinoprost injection. Luteolysis was considered when the serum progesterone concentration was lower than 1 ng/mL 4 days after treatment (Assey et al., 1993; Colazo et al., 2008) .
Experiment 4. Systemic and uterine vein concentrations of PGF 2a and PGFM after IVSM administration
This experiment was performed to test the hypothesis that PGF 2a administered via the IVSM reaches the CL through the systemic circulation. The uterine and jugular veins of a crossbred beef cow without reproductive abnormalities were cannulated according to the procedure described by Lewis et al. (1977) . Briefly, the cow was fasted without access to food and water for 12 h before the administration of anesthesia and the surgical procedures. A vertical incision was made in the left flank to cannulate a branch of the uterine vein at the hilus of the left ovary (Turner and McIlwraith, 1989) . The free end of a silicone tube (2 mm i.d. and 3.2 mm o.d.) was exteriorized through a small incision in the flank and maintained through the infusion of heparinized saline. The jugular vein was also cannulated and maintained by flushing with heparinized saline (Lewis et al., 1977) . Treatments (saline or PGF 2a ) and blood collection started 12 h after surgery. One milliliter of saline was injected via the IVSM route (control treatment); after 3 h and 6 h, the animal was treated with 5 mg of dinoprost IVSM. These 3-h intervals were necessary to completely clear PGF 2a from the systemic circulation (Ferreira and Vane, 1967) . Blood was collected from the jugular and uterine veins at the same time by two different people immediately before each treatment and every 5 min for 40 min. Additionally, blood samples were collected after 120 min of dinoprost injection to verify the decrease in systemic and ovarian concentrations of PGF 2a . The samples were assayed for PGF 2a .
The levels of prostaglandin metabolites were measured to investigate the effects of dose and route of administration on the pulmonary metabolism of PGF 2a (Kindahl et al., 1976) . The jugular vein of a crossbred beef cow with normal estrous cycles was cannulated as described. The cannulated cow was submitted to the following treatments: 25 mg dinoprost IM, 5 mg dinoprost IM, 5 mg dinoprost IVSM, and 1 mL saline IVSM. As stated previously, a 3-h interval was allowed between treatments. Blood samples were collected at 5-min intervals over a 40-min period and were assayed for PGFM.
Blood sampling and hormone assays
Blood samples were collected and allowed to clot for 30 min at room temperature before centrifugation at 1500 Â g for 10 min at room temperature. Serum was placed into cryogenic vials, frozen, and stored at À 80 1C for further analysis. Enzyme immunoassay kits (Cayman Chemical Company, Ann Arbor, MI) were used to quantify PGFM and PGF 2a (Del Vecchio et al., 1992) . The intraassay CV was 7.13% and 2.58%, respectively; sensitivity was 0.015 and 0.010 ng/mL, respectively, for PGFM and PGF 2a . The electrochemiluminescence immunoassay (Roche, Brazil) was performed to determine serum progesterone concentrations (Bossaert et al., 2008) . The intraand inter-assay CV were 2.09% and 1.23%, respectively.
Statistical analysis
All statistical analyses were performed using the SAS software package (SAS Institute Inc., Cary, NC, USA). Data are presented as the mean7SEM unless otherwise indicated. A probability of Pr0.05 was considered statistically significant. The frequency of estrus for the different treatments was analyzed using categorical data-analysis models (CATMOD procedure), and the differences between groups were determined. The analyses of treatment effects on serum progesterone as well as changes in the systemic and local concentrations of PGF 2a over time were organized as splitplot ANOVA data and analyzed using mixed models (Littell et al., 1998) . The model for a repeated-measures experiment was as follows: g ijk ¼m þa i þt k þ(at) ik þe ijk , where g ijk is the response at time k for animal j in treatment group i, m is the overall mean, a i is a fixed effect of treatment i, t k is a fixed effect of time k, (at) ik is the fixed-interaction effect of treatment i with time k, and e ijk is random error at time k for animal j in treatment i. The main effects of treatment group, hour, and their interaction were determined. Differences between groups at each time point were assessed using the estimate statement. Different covariance structures were tested, and the one with the lowest Akaike's information criterion was used (AIC). Other continuous data were submitted to an ANOVA using the GLM, and multiple comparisons between groups were performed for the least square-adjusted means using the LSMEANS function in SAS statistical software, with the PDIFF option to request p-values for differences.
Results
Experiment 1. Effect of reduced doses of IVSM PGF 2a administration on estrous behavior
The rate of detection of estrus in cows over the first 5 days (control) was 25.6% (497 out of 1937). By five days after the injection of 5 mg dinoprost via IVSM, 68.2% of cows were considered to be in estrus (983 out of 1440) (Fig. 1A) . For the entire period of estrus detection (10 days), a total of 76.4% of cows presented estrus. The rate of estrus from days 1 to 6 was approximately 5% per day (from 4 to 6%); this value increased to 7.9% at day 7 and peaked at 19.9% on day 8 (3 days after prostaglandin injection; Po0.05). This distribution of estrus revealed that the cows were cycling at the beginning of the experiment and that 5 mg of PGF 2a (1/5 of the standard dose) resulted in the induction of estrus (Fig. 1B) .
Experiment 2. Intramuscular vs. intravulvosubmucosal injection of PGF 2a
Before treatment, heifers were observed for estrous behavior for 5 d; at the end of this period, 23.5% of cows were detected to be in estrus (4.7% per day as expected in a cyclic herd). Treatment with 5 mg of dinoprost via IM or IVSM resulted in 54.7% and 47.4% of cows being in estrus, respectively, during the 5 days after PGF 2a administration ( Fig. 2; P40 .05).
Experiment 3. PGF 2a injection (IM or IVSM) at times of low and high corpus luteum sensitivity
Prostaglandin F 2a was injected in 22 beef cows at three doses (0, 5, and 25 mg) using two routes of administration (IM or IVSM) on one of two days of the estrous cycle (day 5 or 10). The pattern of serum progesterone concentration differed in accordance with the dose or day of the estrous cycle but was not affected by administration route. A sharp decline in serum progesterone concentration (less than 1 ng/mL 24 h after treatment) was observed only in the 25-mg dose group (Po0.01). The data obtained from animals that received 5 mg of dinoprost by IM or IVSM injection (n¼ 3/treatment) at day 5 of the estrous cycle (low PGF 2a responsiveness period) are not shown because the CL did not undergo luteolysis (4 days after treatment serum, progesterone concentrations were Z5 ng/mL).
Animals treated at day 10 of the estrous cycle showed lower progesterone concentrations than those in the control group (Po0.05). However, luteolysis (serum progesterone concentrations below 1 ng/mL) was observed in only 3 out of 5 cows (IM) and in 2 out of 5 cows (IVSM) treated with 5 mg (Fig. 3) . The serum progesterone concentrations were not different in cows that did not have luteolysis or in controls 4 days after treatment (data not shown). All cows that received 25 mg IM (standard dose) at day 5 (n¼3) and day 10 (n¼3) underwent luteolysis.
Experiment 4. Systemic and uterine vein concentrations of PGF 2a and PGFM after IVSM administration
The concentrations of PGF 2a did not differ in the jugular and uterine veins after saline or PGF 2a (5 mg) IVSM injections (Fig. 4A) . The concentrations of PGF 2a in the jugular and uterine veins after dinoprost treatment via the IVSM ranged from 0.392 to 1.163 ng/mL, respectively. As expected, after saline treatment, the concentrations of PGF 2a were less than 0.120 ng/mL. In blood samples collected after 120 min of dinoprost treatment, serum PGF 2a concentrations in the (n¼ 1937) and after treatment with 5 mg of dinoprost tromethamine via the intravulvosubmucosal (IVSM) route at day 5, using the 10-day, 1-injection management system. Only cows that were not considered to be in estrus (n¼1440) were treated at day 5. (B) The distribution of estrous behavior among cyclic beef cows (n¼1937) before and after injection with 5 mg of dinoprost via IVSM at day 5. Asterisks (*) indicate significant differences (Pr0.01), and arrows (k) indicate the day of treatment. Fig. 2 . Proportion of cyclic beef heifers showing estrous behavior before (control; n¼ 241) and after treatment with 5 mg of dinoprost tromethamine via the intravulvosubmucosal (IVSM) or intramuscular (IM) route at day 5 using the 10-day, 1-injection management system. Only heifers that were not considered to be in estrus were treated with 5 mg of dinoprost via the IM (n¼95) or IVSM (n ¼97) route at day 5. Asterisks (*) indicate significant differences (P r 0.01). Fig. 3 . Mean serum progesterone concentration (ng/mL) after the administration of dinoprost tromethamine on day 10 of the estrous cycle via the intravulvosubmucosal (IVSM) or intramuscular (IM) route. The animals in the control group were at the same stage of the estrous cycle as the treated animals but were not submitted to any treatment. The asterisk (*) indicates significant differences from the control group (Pr0.05). jugular and uterine veins were 0.133 and 0.226 ng/mL, respectively. We also demonstrated that the concentration of the PGF 2a metabolite (PGFM) had a similar pattern after the administration of 5 mg of dinoprost via IM or IVSM (Fig. 4B) . However, the PGFM pattern was greater with 25-mg IM injection compared to the other treatments.
Discussion
The most important findings in our study were the following: (1) 1/5 of the standard dose of PGF 2a was effective in synchronizing estrous behavior in a large number of animals when injected in cows after day 5 of the estrous cycle by either the IM or IVSM routes; (2) the effectiveness of PGF 2a in inducing luteolysis was dependent of the dose and period of the estrous cycle, regardless of the route; (3) PGF 2a concentrations in the jugular and uterine veins were not different after the IVSM injection of 5 mg of dinoprost; and (4) the PGF 2a metabolite (PGFM) concentration over time was not route dependent but was dose dependent.
Many cows (n ¼1937) were synchronized with PGF 2a via IVSM injection (5 mg dinoprost) using the 10-day, 1-injection management system (Donaldson et al., 1982) . This synchronization system is a good model with which to study the route of PGF 2a injection. Animals were monitored twice a day for 5 days to determine their estrous cyclicity. Over the first 5 d, 5.1% of the cows showed estrous behavior, which confirmed that many of the cows were cycling. On the morning of the fifth day of attempts at estrus detection, dinoprost (5 mg) was administered via the IVSM route. A peak of estrous behavior was observed 3 days after PGF 2a injection. This estrus profile validated the luteolytic efficiency of the reduced dose of PGF 2a . Low doses of PGF 2a and alternative routes of administration have been used extensively by veterinary practitioners in order to reduce costs (Colazo et al., 2002a (Colazo et al., , 2002b Horta et al., 1986; Inskeep, 1973; Louis et al., 1974) . With this aim, IVSM has been the route of choice when using low-dose PGF 2a as a luteolytic agent, mainly in attempts to synchronize estrus among cattle (Alvarez et al., 1991; Chohan, 1998; Horta et al., 1986; Ono et al., 1982; Suñ e et al., 1985) .
The local vascular countercurrent of PGF 2a transport from the uterine venous blood to the ovarian arterial blood is well established (Barrett et al., 1971; Hixon and Hansel, 1974; Land et al., 1976; McCracken et al., 1972 McCracken et al., , 1981 . Recently, it has been demonstrated that the transport of PGF 2a from the uterus to the ovary is regulated by PGF 2a transporter protein-mediated mechanisms at the time of luteolysis (Lee et al., 2010) . Thus, the IVSM route has been used based on the hypothesis that PGF 2a would reach the ovary, avoiding pulmonary clearance. Consequently, a low dose of PGF 2a would be enough to induce luteolysis. However, in the second experiment, we demonstrated that 5 mg of PGF 2a (1/5 of the standard dose) administered IM or IVSM in heifers resulted in similar rates of estrous behavior, as reported by Alvarez et al. (1991) . The distribution pattern of cows in estrus was similar to that observed in the first experiment, and the heifers were also cyclic (4.7% of estrus per day in the first 5 d). Combining the results of both routes (IM and IVSM), the estrus rate was 16% three days after the administration of 5 mg of dinoprost, as expected after PGF 2a treatment in the 10-day, 1-injection management system (Donaldson et al., 1982) . The number of animals in estrus peaked at day 8, indicating that the 5 mg of dinoprost administered via the IM and IVSM routes induced luteolysis at the same rate. This finding provides indirect evidence that PGF 2a given via the IVSM route is absorbed and reaches the ovary through the systemic circulation rather than through any local communication system.
For the past 30 years, there has been controversy about the rationale of using reduced doses of PGF 2a via the IVSM route (Alvarez et al., 1991; Chohan, 1998; Colazo et al., 2002b) . A low dose of PGF 2a is required when it is infused throughout the uterus (Louis et al., 1974 ; Tervit et al., 1973) or injected into the uterine wall (Inskeep, 1973) . Furthermore, a low dose of PGF 2a administered through the IVSM route was as efficient as the recommended IM dose in inducing labor in swine (Friendship et al., 1990) . The stage of the CL might be related to the effectiveness of 5 mg of dinoprost administered via the IVSM route in inducing luteolysis. For this reason, we tested the hypothesis that the CL was less sensitive to the low dose of PGF 2a during the early stages of its formation. Cows treated with reduced doses during a period of lower CL sensitivity (day 5 of the estrous cycle) did not exhibit functional luteolysis regardless of the administration route (IM or IVSM). Lack of luteolytic effect was also reported when low doses of PGF 2a were administered subcutaneously or IM at day 5 or 7 of the estrous cycle (Berardinelli and Adair, 1989; Colazo et al., 2002a) . However, in this study, luteolysis occurred in 5 out of 10 cows treated with 5 mg (IVSM or IM) at day 10 of the estrous cycle. In contrast, all animals, regardless of the timing (day 5 or 10), responded to a 25-mg injection of dinoprost. Additionally, cows treated at day 5 with 5 mg IM or IVSM showed a serum progesterone concentration of 6.470.3 ng/mL 4 days after treatment; these values are normally observed at day 9 of the estrous cycle (Stabenfeldt et al., 1969) . Consequently, the age of the CL has to be considered as an important factor that influences the effectiveness of a reduced dose of PGF 2a (Alvarez et al., 1991; Chohan, 1998; Colazo et al., 2002a) .
Blood serum samples obtained from the jugular and uterine veins were used to determine whether the injected PGF 2a was reaching the ovaries through the systemic or the ovarian circulatory pathway (Hixon and Hansel, 1974; Lewis et al., 1977) . The surgery for uterine vein cannulation was extremely invasive. Due to animal welfare considerations, only one animal was cannulated. Using the same approach, Hixon and Hansel (1974) demonstrated that PGF 2a administered in an intrauterine fashion was transferred from the uterus to the ovarian artery before reaching the systemic circulation in cattle. Despite the countercurrent mechanism and the vascular anatomy between the vulva and the uterus, our results indicated that there was no noteworthy local transfer of PGF 2a from the IVSM to the ovaries. Therefore, we tested the hypothesis that PGF 2a injected via the IVSM reaches the CL through the systemic circulation. The concentrations of PGF 2a did not differ in the jugular and uterine veins over time when dinoprost was injected via IVSM.
The pattern of PGFM in the jugular vein (an indicator of PGF 2a release into the circulation) (Kindahl et al., 1976) was similar over time after treatment with 5 mg of dinoprost via either the IM or IVSM route. These results provide further evidence that PGF 2a reaches the circulatory system before the ovary and support the absence of a route (IM or IVSM) effect. The goal of this experiment was to confirm the results from a PGF 2a experiment using a less invasive approach. Despite the use of a single cow, all results from the current study (estrous behavior, PGF 2a and PGFM concentrations) are in agreement and clearly demonstrated that PGF 2a reached the systemic circulation before reaching the ovary after administration through the IVSM route.
In summary, this is the first study that investigated the PGF 2a pathway (systemic or local circulation) after IVSM PGF 2a treatment. We also demonstrated with a large number of animals that the dose of PGF 2a could be reduced when using the 10-day, 1-injection management system. The IVSM route could be useful to avoid the muscle tissue damage caused by dinoprost (Fajt et al., 2011) when applied in commercial systems. Furthermore, the reflux of a small volume (1 mL) is more likely when administering the drug through the IM route when compared to the IVSM route. However, the IVSM is not as practical as IM administration in a large number of animals. In conclusion, PGF 2a injected via IVSM reached the systemic circulation before reaching the ovary. These data also demonstrated that the luteolytic effectiveness of reduced doses of dinoprost is mainly dependent on the period of the estrous cycle and is not affected by IVSM or IM administration routes.
